Identification of new citrulline-specific autoantibodies, which bind to human arthritic cartilage, by mass spectrometric analysis of citrullinated type ii collagen

Arthritis and Rheumatology

Volumn 66, Issue 6, 2014, Pages 1440-1449

  Haag, Sabrina ^a   Schneider, Nadine ^b   Mason, Daniel E ^c   Tuncel, Jonatan ^a   Andersson, Ida E ^a   Peters, Eric C ^c   Burkhardt, Harald ^b   Holmdahl, Rikard ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CITRULLINATED PROTEIN ANTIBODY; CITRULLINE; COLLAGEN TYPE 2; IMMUNOGLOBULIN G; PROTEIN ANTIBODY; PROTEIN ARGININE DEIMINASE; PROTEIN ARGININE DEIMINASE 2; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; ARTICLE; CARTILAGE; CIRCULAR DICHROISM; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN PURIFICATION; IMMUNOREACTIVITY; IN VITRO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DENATURATION; PURIFICATION; RAT; RHEUMATOID ARTHRITIS; TANDEM MASS SPECTROMETRY; THERMOSTABILITY; TRIPLE HELIX;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CARTILAGE, ARTICULAR; CASE-CONTROL STUDIES; CITRULLINE; COLLAGEN TYPE II; EPITOPES; HUMANS; HYDROLASES; IMMUNOGLOBULIN G; RATS; TANDEM MASS SPECTROMETRY;

EID: 84901594085     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38383     Document Type: Article

References (53)

1. Gregersen PK, Silver J, Winchester RJ,. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.
2. Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee HS, Jia X, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44: 291-6.
3. Conrad K, Roggenbuck D, Reinhold D, Dorner T,. Profiling of rheumatoid arthritis associated autoantibodies. Autoimmun Rev 2010; 9: 431-5.
4. Van Venrooij WJ, van Beers JJ, Pruijn GJ,. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011; 7: 391-8.
5. Avouac J, Gossec L, Dougados M,. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65: 845-51.
6. Pruijn GJ, Wiik A, van Venrooij WJ,. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010; 12: 203.
7. Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005; 64: 1199-204.
8. Van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, Onnekink C, Schwarte CM, Verpoort KN, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010; 69: 1554-61.
9. Van de Stadt LA, de Koning MH, van de Stadt RJ, Wolbink G, Dijkmans BA, Hamann D, et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 2011; 63: 3226-33.
10. Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 2012; 7: e35296.
11. Brink M, Hansson M, Mathsson L, Jakobsson PJ, Holmdahl R, Hallmans G, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013; 65: 899-910.
12. Van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 2232-41.
13. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T,. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 196-201.
14. Syversen SW, Goll GL, van der Heijde D, Landewe R, Lie BA, Odegard S, et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010; 69: 345-51.
15. Mathsson L, Mullazehi M, Wick MC, Sjoberg O, van Vollenhoven R, Klareskog L, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008; 58: 36-45.
16. Van Beers JJ, Willemze A, Stammen-Vogelzangs J, Drijfhout JW, Toes RE, Pruijn GJ,. Anti-citrullinated fibronectin antibodies in rheumatoid arthritis are associated with human leukocyte antigen-DRB1 shared epitope alleles. Arthritis Res Ther 2012; 14: R35.
17. Scherer HU, van der Woude D, Willemze A, Trouw LA, Knevel R, Syversen SW, et al. Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Ann Rheum Dis 2011; 70: 1461-4.
18. Lundberg K, Bengtsson C, Kharlamova N, Reed E, Jiang X, Kallberg H, et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis 2013; 72: 652-8.
19. Vossenaar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004; 63: 373-81.
20. Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Mechin MC, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007; 56: 3541-53.
21. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008; 205: 967-79.
22. Kinloch AJ, Alzabin S, Brintnell W, Wilson E, Barra L, Wegner N, et al. Immunization with Porphyromonas gingivalis enolase induces autoimmunity to mammalian α-enolase and arthritis in DR4-IE-transgenic mice. Arthritis Rheum 2011; 63: 3818-23.
23. Haag S, Uysal H, Backlund J, Tuncel J, Holmdahl R,. Human α-enolase is immunogenic, but not arthritogenic, in HLA- DR4-transgenic mice: comment on the article by Kinloch et al [letter]. Arthritis Rheum 2012; 64: 1689-91.
24. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006; 116: 961-73.
25. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012; 122: 1791-802.
26. Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engstrom A, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 2009; 206: 449-62.
27. Brodsky B, Persikov AV,. Molecular structure of the collagen triple helix. Adv Protein Chem 2005; 70: 301-39.
28. Burkhardt H, Koller T, Engstrom A, Nandakumar KS, Turnay J, Kraetsch HG, et al. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis Rheum 2002; 46: 2339-48.
29. Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR, Holmdahl R,. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005; 35: 1643-52.
30. Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2009; 68: 736-43.
31. Snir O, Widhe M, Hermansson M, von Spee C, Lindberg J, Hensen S, et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010; 62: 44-52.
32. Andersson M, Holmdahl R,. Analysis of type II collagen-reactive T cells in the mouse. I. Different regulation of autoreactive vs. non-autoreactive anti-type II collagen T cells in the DBA/1 mouse. Eur J Immunol 1990; 20: 1061-6.
33. Fujisaki M, Sugawara K,. Properties of peptidylarginine deiminase from the epidermis of newborn rats. J Biochem 1981; 89: 257-63.
34. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003; 62: 835-41.
35. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
36. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al. Antibodies to citrullinated α-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008; 58: 3009-19.
37. Yoshida M, Tsuji M, Kurosaka D, Kurosaka D, Yasuda J, Ito Y, et al. Autoimmunity to citrullinated type II collagen in rheumatoid arthritis. Mod Rheumatol 2006; 16: 276-81.
38. Senshu T, Akiyama K, Kan S, Asaga H, Ishigami A, Manabe M,. Detection of deiminated proteins in rat skin: probing with a monospecific antibody after modification of citrulline residues. J Invest Dermatol 1995; 105: 163-9.
39. Stensland M, Holm A, Kiehne A, Fleckenstein B,. Targeted analysis of protein citrullination using chemical modification and tandem mass spectrometry. Rapid Commun Mass Spectrom 2009; 23: 2754-62.
40. De Ceuleneer M, De Wit V, Van Steendam K, Van Nieuwerburgh F, Tilleman K, Deforce D,. Modification of citrulline residues with 2,3-butanedione facilitates their detection by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2011; 25: 1536-42.
41. Schulte S, Unger C, Mo JA, Wendler O, Bauer E, Frischholz S, et al. Arthritis-related B cell epitopes in collagen II are conformation-dependent and sterically privileged in accessible sites of cartilage collagen fibrils. J Biol Chem 1998; 273: 1551-61.
42. Sugawara K, Oikawa Y, Ouchi T,. Identification and properties of peptidylarginine deiminase from rabbit skeletal muscle. J Biochem 1982; 91: 1065-71.
43. Ackerman MS, Bhate M, Shenoy N, Beck K, Ramshaw JA, Brodsky B,. Sequence dependence of the folding of collagen-like peptides: single amino acids affect the rate of triple-helix nucleation. J Biol Chem 1999; 274: 7668-73.
44. Kramer RZ, Bella J, Mayville P, Brodsky B, Berman HM,. Sequence dependent conformational variations of collagen triple-helical structure. Nat Struct Biol 1999; 6: 454-7.
45. Okuyama K, Wu G, Jiravanichanun N, Hongo C, Noguchi K,. Helical twists of collagen model peptides. Biopolymers 2006; 84: 421-32.
46. Leikina E, Mertts MV, Kuznetsova N, Leikin S,. Type I collagen is thermally unstable at body temperature. Proc Natl Acad Sci U S A 2002; 99: 1314-8.
47. Nandakumar KS, Svensson L, Holmdahl R,. Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol 2003; 163: 1827-37.
48. Nandakumar KS, Bajtner E, Hill L, Bohm B, Rowley MJ, Burkhardt H, et al. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis Rheum 2008; 58: 184-96.
49. Banda NK, Hyatt S, Antonioli AH, White JT, Glogowska M, Takahashi K, et al. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol 2012; 188: 1469-78.
50. Blom AM, Nandakumar KS, Holmdahl R,. C4b-binding protein (C4BP) inhibits development of experimental arthritis in mice. Ann Rheum Dis 2009; 68: 136-42.
51. Kagari T, Tanaka D, Doi H, Shimozato T,. Essential role of Fcγ receptors in anti-type II collagen antibody-induced arthritis. J Immunol 2003; 170: 4318-24.
52. Murphy KM, Travers P, Walport M, Janeway C,. Janeway's immunobiology. 8th ed. New York: Garland Science; 2011.
53. Arend WP, Firestein GS,. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol 2012; 8: 573-86.